Clinical Trial

Effect of Prehabilitation on Recovery Outcomes in Post-Surgical Cervical Cancer Women

Study acronym: PROP-CC
Completed
View on ClinicalTrials.gov →
Summary
This parallel-group randomized controlled trial evaluated the effectiveness of a four-week multimodal prehabilitation programme on pelvic function and quality of life among women with cervical cancer undergoing radical hysterectomy. Thirty-nine eligible participants were randomly allocated to either the intervention group or the control group. The intervention group received a supervised multimodal prehabilitation programme comprising aerobic exercise, pelvic floor muscle training, progressive resistance training, flexibility exercises, breathing exercises, and patient education for four weeks prior to surgery, while the control group received standard preoperative care. Following radical hysterectomy, both groups underwent an identical postoperative rehabilitation programme. Pelvic function was assessed using transabdominal ultrasound by measuring bladder base displacement during voluntary pelvic floor muscle contraction. Pelvic floor symptoms were evaluated using the Pelvic Floor Distress Inventory-20 (PFDI-20), and health-related quality of life was assessed using a validated quality-of-life questionnaire. Outcome assessments were performed at baseline, four weeks before surgery prior to initiation of the intervention, and repeated four weeks after surgery. The study investigated whether a structured prehabilitation programme improved pelvic function, reduced pelvic floor-related symptoms, and enhanced postoperative quality of life compared with standard preoperative care among women undergoing radical hysterectomy for cervical cancer.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2026-02-04; most recent amendment 2026-07-14.
Trial Details
NCT Number NCT07398313
Lead Sponsor Saveetha University
Conditions Cervical Adenocarcinoma, Hysterectomy, Cervical Cancer
Enrollment 34 participants
Start Date 2025-06-17
Primary Completion 2026-02-07 (estimated)
Study Completion 2026-04-22 (estimated)
Updated on ClinicalTrials.gov 2026-07-16